Previously, we performed whole-exome sequencing on tissue samples from a cohort of patients with ovarian cancer and found that platinum-sensitive patients show a significantly higher missense mutation rate of TBC1D22A than platinum-resistant patients. This evidence concerns the gene TBC1D22A and ovarian carcinoma.